HaloVax is a special purpose subsidiary of Voltron Therapeutics which reached an agreement with Hoth Therapeutics to co-develop a SARS-CoV-2 vaccine using Voltron's self-assembling vaccine technology.
The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapeutics Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized cellular immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.
The company was set up to apply Voltron Therapeutics's proprietary self-assembling vaccine (SAV) platform to develop a vaccine for SARS-CoV-2, the virus which causes COVID-19. The technology was developed out of Massachusetts General Hospital and was exclusively licensed to Voltron.
HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ: HOTH) (previously released) to advance an application of VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection.
Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.